INKT Stock Price, MiNK Therapeutics, Inc. Quote, Chart

Market Summary

USD1.01-0.03

Delayed

-2.88%

INKT Stock Price

View Fullscreen

INKT RSI Chart

INKT Valuation

Market Cap

35.1M

Price/Earnings (Trailing)

-1.7

Price/Free Cashflow

-2.5

INKT Price/Earnings (Trailing)

INKT Profitability

Return on Equity

101.41%

Return on Assets

-298.6%

Free Cashflow Yield

-39.95%

INKT Fundamentals

INKT Earnings

Earnings (TTM)

-20.6M

Earnings Growth (Yr)

32.94%

Earnings Growth (Qtr)

30.14%

Breaking Down INKT Revenue

Last 7 days

12.2%

Last 30 days

9.8%

Last 90 days

9.8%

Trailing 12 Months

-41.3%

How does INKT drawdown profile look like?

INKT Financial Health

Current Ratio

0.54

INKT Investor Care

Shares Dilution (1Y)

0.89%

Diluted EPS (TTM)

-0.59

Tracking the Latest Insider Buys and Sells of MiNK Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	corvese brian	acquired	17,875	0.95	18,816	-
Mar 01, 2024	ryan barbara	acquired	17,750	0.95	18,685	-
Mar 01, 2024	wiinberg ulf	acquired	15,000	0.95	15,790	-
Mar 01, 2024	behner peter	acquired	15,375	0.95	16,185	-
Dec 01, 2023	corvese brian	acquired	17,875	1.04	17,188	-
Dec 01, 2023	wiinberg ulf	acquired	15,001	1.04	14,424	-
Dec 01, 2023	ryan barbara	acquired	17,750	1.04	17,068	-
Dec 01, 2023	behner peter	acquired	15,375	1.04	14,784	-
Oct 16, 2023	agenus inc	bought	471	1.0992	429	-
Oct 13, 2023	agenus inc	bought	21,310	1.1	19,373	-

Which funds bought or sold INKT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-19,672	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	unchanged	-	-258	1,406	-%
May 15, 2024	Royal Bank of Canada	reduced	-80.95	-1,000	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-50.62	-26,400	18,901	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-22.06	-7,262	14,199	-%
May 15, 2024	ORACLE INVESTMENT MANAGEMENT INC	sold off	-100	-39,481	-	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-30.00	168	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	18,254	18,254	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	unchanged	-	-8,778	49,313	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	1.07	-1,667	10,042	-%

Are Funds Buying or Selling INKT?

Are funds buying INKT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INKT

No. of Funds

Unveiling MiNK Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armen garo h	9.68%	3,514,320	SC 13D
May 26, 2023	agenus inc	62.5%	21,522,157	SC 13D/A
May 03, 2023	agenus inc	62%	21,344,685	SC 13D/A
Feb 14, 2022	armen garo h	7.82%	2,616,882	SC 13G

Recent SEC filings of MiNK Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 30, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to MiNK Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

MiNK Therapeutics, Inc. News

Latest updates

MiNK Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	51.4%	7.00	5.00	7.00	12.00	17.00	21.00	25.00	31.00	36.00	40.00	4.00	5.00
Current Assets	66.7%	6.00	4.00	6.00	11.00	16.00	20.00	24.00	30.00	35.00	40.00	3.00	4.00
Cash Equivalents	72.8%	6.00	3.00	6.00	11.00	15.00	20.00	24.00	30.00	35.00	39.00	1.00	3.00
Net PPE	-6.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
Current Liabilities	-2.6%	11.00	11.00	10.00	11.00	11.00	13.00	18.00	17.00	19.00	16.00	81.00	14.00
Shareholder's Equity	-12.4%	-20.30	-18.06	-	-	-4.48	-0.40	7.00	14.00	17.00	24.00	-	-
Retained Earnings	-2.8%	-137	-133	-127	-122	-116	-110	-103	-96.80	-90.72	-82.95	-77.18	-52.74
Additional Paid-In Capital	1.3%	117	116	115	114	113	111	110	109	108	107	1.00	0.00
Accumulated Depreciation	10.0%	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Shares Outstanding	-100.0%	-	35.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00	33.00	24.00	24.00
Float	-	-	-	-	21.00	-	-	-	7.00	-	-	43.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	16.3%	-2,542	-3,035	-4,209	-4,151	-4,366	-4,430	-5,614	-4,625	-4,196	-1,702	-3,495	-3,420	-4,208	-	-
Share Based Compensation	-46.3%	592	1,102	939	898	921	668	773	801	786	667	387	407	283	-	-
Cashflow From Investing	-	-	-	-23.04	-37.02	-13.50	-127	-59.79	-	-	277*	-111	-97.92	-39.52	-	-
Cashflow From Financing	250344900.0%	5,007	-2*	3.00	-75.70	-334	111*	494*	-156	689*	39,797	2,783	4,352	2,324	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INKT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 2,549,482	$ 4,193,562
General and administrative	1,280,432	1,660,534
Operating loss	(3,829,914)	(5,854,096)
Other income, net:
Interest income, net	16,619	168,055
Net loss	$ (3,813,295)	$ (5,686,041)
Per common share data:
Basic net loss per common share	$ (0.11)	$ (0.17)
Diluted net loss per common share	$ (0.11)	$ (0.17)
Weighted average number of common shares outstanding, basic	34,642,915	33,966,921
Weighted average number of common shares outstanding, diluted	34,642,915	33,966,921
Other comprehensive income (loss):
Foreign currency translation gain (loss)	$ 45,167	$ (81,335)
Comprehensive loss	$ (3,768,128)	$ (5,767,376)

INKT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 5,817,080	$ 3,367,229
Prepaid expenses	59,394	53,111
Other current assets	122,477	177,964
Total current assets	5,998,951	3,598,304
Equipment, net of accumulated depreciation of $545,095 and $495,638 at March 31, 2024 and December 31, 2023, respectively	894,992	953,977
Total assets	6,893,943	4,552,281
LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	3,486,999	3,911,973
Accrued liabilities	5,282,707	5,037,361
Other current liabilities	2,338,554	2,453,251
Total current liabilities	11,108,260	11,402,585
Related party note	4,211,566
Other long-term liabilities	31,600	48,072
Due to related parties	11,841,724	11,157,073
Commitments and contingencies
STOCKHOLDERS' DEFICIT
Common stock, par value $0.00001 per share; 150,000,000 shares authorized; 34,699,056 and 34,599,119 shares issued at March 31, 2024 and December 31, 2023, respectively	347	346
Additional paid-in capital	117,296,454	115,772,085
Accumulated other comprehensive loss	(385,780)	(430,947)
Accumulated deficit	(137,210,228)	(133,396,933)
Total stockholders' deficit	(20,299,207)	(18,055,449)
Total liabilities and stockholders' deficit	$ 6,893,943	$ 4,552,281

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

CEO	Dr. Jennifer S. Buell Ph.D.
WEBSITE	https://minktherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	37

MiNK Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for MiNK Therapeutics, Inc.? What does INKT stand for in stocks?

INKT is the stock ticker symbol of MiNK Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MiNK Therapeutics, Inc. (INKT)?

As of Fri May 17 2024, market cap of MiNK Therapeutics, Inc. is 35.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INKT stock?

You can check INKT's fair value in chart for subscribers.

What is the fair value of INKT stock?

You can check INKT's fair value in chart for subscribers. The fair value of MiNK Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MiNK Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INKT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MiNK Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether INKT is over valued or under valued. Whether MiNK Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact MiNK Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INKT.